SAT exhibited a significant increase in OLFM2 mRNA expression in the SS and NASH groups compared to the NL and NW control groups, as shown in Figure 3C. However, in VAT, we observed nonsignificant differences between the groups (Figure 3D). The gene discussed is OLFM2; the disease is metabolic dysfunction-associated steatohepatitis.